Literature DB >> 8730117

Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture.

C P Denton1, S Xu, K I Welsh, J D Pearson, C M Black.   

Abstract

OBJECTIVE: We established a co-culture system to investigate endothelial cell-fibroblast interaction in scleroderma (systemic sclerosis, SSc). Such a system allows reciprocal interaction between these cells. The pattern of phenotypic modulation for normal and SSc fibroblasts in co-culture was compared.
METHODS: A virally transformed human umbilical vein endothelial cell (HUVEC) derived cell line (1E-7) was cultured on nitrocellulose membrane inserts above dermal fibroblast monolayers. The effect of co-culture on fibroblast number, [3H]-thymidine ([3H]-TdR) incorporation, and collagen (type I) production were compared for 10 SSc and 5 control cell lines. Co-culture with the epithelial lines A549 and A431, and nontransformed HUVEC, was also investigated.
RESULTS: We observed a statistically significant increase in cell number and a reduction in collagen production for SSc, but not control, fibroblasts co-cultured with endothelial cells. This co-culture also promoted [3H]-TdR incorporation in both SSc and control fibroblasts. While epithelial cell lines did not influence fibroblast cell number, collagen production by SSc fibroblasts was diminished by A549.
CONCLUSIONS: Endothelial cell derived soluble factors modulated fibroblast properties in co-culture, and the different response of SSc compared with normal fibroblasts provides further evidence for a link between endothelial and fibroblast dysfunction in this disease. However, similar effects on SSc fibroblast collagen production were also observed for some epithelial cells, suggesting that modulation of fibroblast properties is not restricted to cells of endothelial origin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730117

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  Y Renaudineau; R Revelen; Y Levy; K Salojin; B Gilburg; Y Shoenfeld; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

Authors:  D Farge; J Passweg; J M van Laar; Z Marjanovic; C Besenthal; J Finke; H H Peter; F C Breedveld; W E Fibbe; C Black; C Denton; I Koetter; F Locatelli; A Martini; A V N Schattenberg; F van den Hoogen; L van de Putte; F Lanza; R Arnold; P A Bacon; S Bingham; F Ciceri; B Didier; J L Diez-Martin; P Emery; W Feremans; B Hertenstein; F Hiepe; R Luosujärvi; A Leon Lara; A Marmont; A M Martinez; H Pascual Cascon; C Bocelli-Tyndall; E Gluckman; A Gratwohl; A Tyndall
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

3.  Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers.

Authors:  C P Denton; X Shi-Wen; A Sutton; D J Abraham; C M Black; J D Pearson
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 4.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

5.  Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Authors:  Christopher P Denton; Voon H Ong; Shiwen Xu; Haiyin Chen-Harris; Zora Modrusan; Robert Lafyatis; Dinesh Khanna; Angelika Jahreis; Jeffrey Siegel; Thierry Sornasse
Journal:  Ann Rheum Dis       Date:  2018-05-31       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.